{"organizations": [], "uuid": "c2bc73219cad9c90b8858ded29b1442be3721e5f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/fresenius-alleges-blatant-fraud-at-aband/fresenius-alleges-blatant-fraud-at-abandoned-target-akorn-idUSL1N1S90QI", "country": "US", "domain_rank": 408, "title": "Fresenius alleges \"blatant fraud\" at abandoned target Akorn", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T17:34:00.000+03:00", "replies_count": 0, "uuid": "c2bc73219cad9c90b8858ded29b1442be3721e5f"}, "author": "", "url": "https://www.reuters.com/article/fresenius-alleges-blatant-fraud-at-aband/fresenius-alleges-blatant-fraud-at-abandoned-target-akorn-idUSL1N1S90QI", "ord_in_thread": 0, "title": "Fresenius alleges \"blatant fraud\" at abandoned target Akorn", "locations": [], "entities": {"persons": [{"name": "tom hals", "sentiment": "none"}], "locations": [{"name": "del.", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "wilmington", "sentiment": "none"}, {"name": "delaware", "sentiment": "none"}, {"name": "wilmington", "sentiment": "none"}], "organizations": [{"name": "akorn", "sentiment": "negative"}, {"name": "fresenius", "sentiment": "negative"}, {"name": "akorn inc", "sentiment": "none"}, {"name": "court of chancery", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "akorn reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2, 2018 / 2:35 PM / Updated 11 minutes ago Fresenius alleges \"blatant fraud\" at abandoned target Akorn Reuters Staff 1 Min Read\nWILMINGTON, Del., May 2 (Reuters) - German healthcare group Fresenius alleged it uncovered “blatant fraud at the very top level” of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a filing in Delaware’s Court of Chancery.\nFresenius abandoned the merger agreement last month, and Akorn has sued to try to hold Fresenius to the deal. (Reporting by Tom Hals in Wilmington, Delaware)", "external_links": [], "published": "2018-05-02T17:34:00.000+03:00", "crawled": "2018-05-02T17:52:43.009+03:00", "highlightTitle": ""}